

# ORBITAL NK/T CELL LYMPHOMA AS FIRST PRESENTATION OF HIV IN OVERSEAS VISITOR

---

ASHM Case Presentation Breakfast  
8<sup>th</sup> November 2017

Shu Jin Tan  
Infectious Diseases Registrar  
Royal Perth Hospital  
Western Australia

## Mrs CN - 1<sup>st</sup> Presentation

- 37-year-old Zimbabwean female visitor
  - 1 week of frontal headache, subjective fever, nasal congestion
  - 4 days of right-sided facial pain and swelling
- Past medical history:
  - Recurrent sinusitis - maxillary sinus surgery
- Nil regular medications
- Lives with husband and 3 children



---

## 1<sup>st</sup> presentation

- Examination findings:
  - Right peri-orbital swelling
  - No cranial neuropathy
  - Purulence within right maxillary antrum
- CT head – pansinusitis
- Diagnosis: Right sinogenic peri-orbital cellulitis

---

## 1<sup>st</sup> Presentation


- Management:
  - Intravenous piperacillin/tazobactam
  - Single dose intravenous dexamethasone
  - Xylometazoline nasal spray
- Discharged home 36 hours later
  - Oral amoxicillin/clavulanic acid
  - Nasal decongestant

## 2<sup>nd</sup> Presentation – 6 days later

- Recurrence of right periorbital swelling and pain
- Examination findings
  - Normal vision 6/6
  - Mild infra orbital cellulitis
  - Right periorbital swelling
  - No cranial neuropathy

## 2<sup>nd</sup> Presentation – 6 days later

- CT head



- Blood tests

- WCC -  $5.01 \times 10^9/L$
- Lymphocytes -  $0.92 \times 10^9/L$
- C-reactive protein - 57mg/L

- Incision and drainage
- Intravenous piperacillin/tazobactam

## Progress

- Right nasal tissue culture:
  - Methicillin susceptible *Staphylococcus aureus*
  - *Enterococcus faecalis*
  - Acid fast bacilli not seen, no fungal growth



- Ongoing fevers, progressive lymphopenia

November 2016  
18

## Further investigation

HIV Serology (CMIA): HIV-1/2 antigen/antibody	Reactive
HIV-1/2 Western Blot:	
p17..:	NOT Detected
p24..:	Detected
p55..:	Equivocal
p31..:	Detected
p51..:	Equivocal
p66..:	Detected
gp41..:	Detected
gp120:	Detected
gp160:	Detected
HIV-2:	NOT Detected
Western Blot Interpretation:	POSITIVE
HIV-1 Antibody . . . Detected	

## HIV work up


- CD 4 absolute count –  $26 \times 10^6/L$  (2%)
  - Viral load – 281,838 copies/ml
  - No previous exposure to Hepatitis B or C
  - Schistosoma/Strongyloides/Syphillis serology negative
  - Cryptococcal antigen negative
  - Myco/F lytic blood culture collected
- 
- Chest x-ray normal

November 2016

18

## Progress

- Commenced on Atripla, fluconazole for oral candidiasis, azithromycin and cotrimoxazole prophylaxis
- Ongoing intravenous piperacillin/tazobactam






## Progress

- Increased right periorbital swelling
  - Repeat debridement

	28/11
Hb	123
WCC	3.43
Neutrophils	2.52
Platelets	203
ALT	99
ALP	276
GGT	680

- Abdominal ultrasound – no hepatic lesion



## Progress



	28/11	2/12	5/12
Hb	123	91	88
WCC	3.43	3.1	1.79
Neuts	2.52	2.49	0.47
Platelets	203	187	194
ALT	99	185	92
ALP	276	549	621
GGT	680	1270	1500
Ferritin		90800	
LDH		2270	
Triglyceride		1.8	






## Haematology consult

- Possible macrophage activation/haemophagocytic lymphohistiocytosis (HLH)
  - ? HIV associated
  - ? Other co-infection
  - ? Underlying lymphoma
- Bone marrow aspiration and trephine
- Dexamethasone 20mg daily



## In the mean time...

- Histology nasal mucosa:
  - Extra-nodal NK/T cell lymphoma, nasal type
  - CD 2/7/56 + and EBER +
  - Other T cell markers: CD 3/4/5/8 negative
  - T cell gene rearrangement non-contributory
- EBV viral load
  - $2.96 \times 10^2$  IU/ml
- Bone marrow not involved
- PET scan
  - Stage 2 disease



---

## Psychosocial wellbeing


- Confidentiality
  - Family unaware of diagnosis except husband
- Stigmatization and discrimination
- Healthcare cost
  - Antiretrovirals
  - Cost of chemotherapy and choice
  - Inpatient cost

---

## Medicare Ineligible PLHIV

- Jurisdictional arrangement
- Western Australia:  
*“All fees and charges associated with notifiable sexually transmitted disease management are to be waived by the Health Service Provider managing the care of the patient. This applies to all patients regardless of Medicare eligibility status.”<sup>1</sup>*





## Lymphoma management

- What is the cost? What are the options?
- CHOEP Cycle 1
  - Cyclophosphamide, doxorubicin, etoposide, vincristine and prednisolone
  - Antiretrovirals changed to Truvada + Dolutegravir
- Is that the best option?

## Lymphoma treatment - options

### Ideal

- SMILE;
  - Dexamethasone
  - Methotrexate
  - Ifosfamide
  - L-asparaginase
  - Etoposide
- Response Rate 66%<sup>2</sup>
  - 4 cycles + RTX 50Gy
- 5-year overall survival 50%<sup>2</sup>
- TRM >7%!<sup>3</sup>

### Compromise

- CHOEP;
  - Cyclophosphamide
  - Doxorubicin
  - Etoposide
  - Vincristine
  - Prednisolone
- Response rate 58%<sup>3</sup>
  - 4 cycles + RTX 45Gy
- 3-year overall survival 59%<sup>3</sup>
- 65% progressed on treatment<sup>3</sup>

---

## The dilemma...

- HIV treatment fully accessible
- Decision regarding optimal lymphoma treatment influenced by
  - Medical consideration
  - Financial reasons
- Medicare eligible Australian
  - Likely different treatment to what she was offered

---

## HLH in HIV

- 'Secondary' HLH
- Immune dysregulation and excessive inflammation<sup>4</sup>
  - Macrophage activation
  - Lack of negative feedback from NK cells and cytotoxic lymphocytes
- All stages of HIV<sup>5-7</sup>

---

## HLH in HIV

- Trigger:
  - Viruses, bacteria, mycobacteria, fungi, protozoa<sup>8,9</sup>
  - Neoplasm
- Diagnostic challenges
  - Many symptoms can just be HIV itself
- Fulminant and aggressive<sup>10</sup>

---

## NK/T cell lymphoma

- More common in Asia, Central and South America<sup>11-13</sup>
- Limited reports in the HIV +ve population
  - 6/199 (3%) in a 20-year review in South Africa<sup>14</sup>
- Male predominance (2:1)
- EBV +
- Types:
  - Nasal (80%)
  - Non-nasal (20%)
- “Lethal midline granuloma”
- Haemophagocytosis is a late complication

## Back to our patient...



### GALZ - Gays and Lesbians of Zimbabwe

Address: Pvt. Bag A6131, Avondale, Harare  
 Outreach: Services also available in Zimbabwe  
 Telephone: +263 4 741736  
 Fax: +263 4 740610  
 Email: info@galz.co.zw  
 Web: www.galz.co.zw

[VIEW PROFILE](#)

### Women and AIDS Support Network (WASN) Zimbabwe

Address: PO Box 1554, Harare  
 Telephone: +263 4 791401/4  
 Email: director@mweb.co.zw  
 Web: www.wasnzimbabwe.wordpress.com

[VIEW PROFILE](#)

### National AIDS Council

#### Headquarters

Address: 100 Central Ave, Harare  
 Telephone: +263 4 791170-2  
 Fax: +263 4 791243  
 Email: secretariat@nac.org.zw  
 Web: www.nac.org.zw

[VIEW PROFILE](#)

### Zimbabwe AIDS Network

Address: P.O. Box CY 3006, Causeway, Harare  
 Telephone: +263 4 700832  
 Fax: +263 4 775520  
 Email: info@zan.co.zw  
 Web: www.zan.co.zw

[VIEW PROFILE](#)

### SAFAIDS - Southern African HIV and AIDS Information Communications and Knowledge Management

Address: SAFAIDS Regional Office, 17 Beveridge Road, Avondale  
 Telephone: +263 4 336193/4  
 Fax: +263 4 336195  
 Email: info@safaids.net  
 Web: www.safaids.net

[VIEW PROFILE](#)

### Zimbabwe National Network for People Living with HIV/AIDS (ZNNP+)

Address: PO Box 255, Belvedere, Harare  
 Telephone: +263 4 741824  
 Fax: +263 4 741824  
 Email: info.znnp@gmail.com  
 Web: www.znnp.org.zw

[VIEW PROFILE](#)

## Acknowledgements

- Dr Claire Italiano
- Dr Melita Cirillo
- Morgan Bonnett

Thank you!

## References

1. WA Health Fees and Charges Manual 2017/8. <http://ww2.health.wa.gov.au/Reports-and-publications/WA-Health-Fees-and-Charges-Manual>
2. Kwong, Y. L., W. S. Kim, S. T. Lim, et al. 2012. "SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group." *Blood* 120(15):2973-2980.
3. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. *Blood*. 2013;121(25): 4997–5005.
4. Filipovich A et al. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. *Biol Blood Marrow Transplant*. 2010 Jan; 16 (1 Suppl): S82-9.
5. Park KH, Yu HS, Jung SI, et al. Acute human immunodeficiency virus syndrome presenting with hemophagocytic lymphohistiocytosis. *Yonsei Med J* 2008; 49:325–328.
6. Castilletti C, Preziosi R, Bernardini G, et al. Hemophagocytic syndrome in a patient with acute human immunodeficiency virus infection. *Clin Infect Dis* 2004; 38:1792–1793.
7. Sproat LO, Pantanowitz L, Lu CM, Dezube BJ. Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly. *Clin Infect Dis*, 2003, vol. 37 (pg. e170-3)
8. Doyle T et al. Haemophagocytic syndrome and HIV. *Curr Opin Infect Dis*. 2009; 22 (1): 1-6
9. Roupheal NG et al. Infections associated with haemophagocytic syndrome. *Lancet Infect Dis* 2007;7 :814-22.
10. Bhatia S, Bauer F, Bilgrami SA. Candidiasis-associated hemophagocytic lymphohistiocytosis in a patient infected with human immunodeficiency virus. *Clin Infect Dis* 2003 Dec 1;37(11):e161-6.
11. Laurini JA et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. *Blood*. 2012; 120 (24): 4795-801.
12. Au WY et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single centre experience of 10 years. *Ann Oncol*. 2005; 16(2): 206
13. Au WY et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell lymphoma project. *Blood*. 2009; 113 (17): 3931.
14. Alli N, Meer S. Head and neck lymphomas: A 20-year review in an Oral Pathology Unit, Johannesburg, South Africa, a country with the highest global incidence of HIV/AIDS. *Oral Oncol* 2017; 67: 17-23
15. Perry AM, Diebold J, Nathwani BN et al. Non-Hodgkin lymphoma in the developing world: 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. *Haematologica*. 2016; 101 (10): 1244-1250.
16. National AIDS manual. HIV & AIDS services worldwide. <http://www.aidsmap.com/resources/HIV-AIDS-services-worldwide/page/1412417/>
17. Avert. Global information and education on HIV and AIDS. <https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/zimbabwe>